These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 27329597)

  • 1. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
    Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
    Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
    Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
    Abdul Rahim SA; Dirkse A; Oudin A; Schuster A; Bohler J; Barthelemy V; Muller A; Vallar L; Janji B; Golebiewska A; Niclou SP
    Br J Cancer; 2017 Sep; 117(6):813-825. PubMed ID: 28797031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
    Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
    Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
    Xu H; Rahimpour S; Nesvick CL; Zhang X; Ma J; Zhang M; Zhang G; Wang L; Yang C; Hong CS; Germanwala AV; Elder JB; Ray-Chaudhury A; Yao Y; Gilbert MR; Lonser RR; Heiss JD; Brady RO; Mao Y; Qin J; Zhuang Z
    Oncotarget; 2015 May; 6(14):11882-93. PubMed ID: 25957416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
    Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
    Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
    Ramezani S; Vousooghi N; Ramezani Kapourchali F; Yousefzadeh-Chabok S; Reihanian Z; Alizadeh AM; Khodayari S; Khodayari H
    Life Sci; 2019 Dec; 239():116880. PubMed ID: 31678282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
    Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
    Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis.
    Carpenter RL; Paw I; Zhu H; Sirkisoon S; Xing F; Watabe K; Debinski W; Lo HW
    Oncotarget; 2015 Sep; 6(26):22653-65. PubMed ID: 26093087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
    Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
    Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
    de Groot J; Liang J; Kong LY; Wei J; Piao Y; Fuller G; Qiao W; Heimberger AB
    Oncotarget; 2012 Sep; 3(9):1036-48. PubMed ID: 23013619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The angiogenic switch leads to a metabolic shift in human glioblastoma.
    Talasila KM; Røsland GV; Hagland HR; Eskilsson E; Flønes IH; Fritah S; Azuaje F; Atai N; Harter PN; Mittelbronn M; Andersen M; Joseph JV; Hossain JA; Vallar L; Noorden CJ; Niclou SP; Thorsen F; Tronstad KJ; Tzoulis C; Bjerkvig R; Miletic H
    Neuro Oncol; 2017 Mar; 19(3):383-393. PubMed ID: 27591677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia.
    Mao XG; Xue XY; Wang L; Zhang X; Yan M; Tu YY; Lin W; Jiang XF; Ren HG; Zhang W; Song SJ
    Neuro Oncol; 2013 Jul; 15(7):865-79. PubMed ID: 23645533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.